NCT03508765Completed
Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation
Source: ClinicalTrials.gov · Last updated 8 Mar 2024
Brief summary (registry, in English)
The purpose of this study is to learn about possible changes in thinking (cognitive) abilities, such as memory skills, and in brain anatomy and function, in adults with multiple myeloma who are treated with high-dose chemotherapy followed by ASCT.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 11 Apr 2018
- Start date
- 27 Mar 2018
- Primary completion date
- 6 Mar 2024
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Multiple myeloma
- NCT number
- NCT03508765
What you commit to
- Study type: Interventional
- Participants enrolled: 18
- From 27 Mar 2018 to the primary completion date, 6 Mar 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- As per patient report or as confirmed by the medical record, if the patient is taking anti-depression or anti-anxiety medication, \< 2 months on these medications or a change in the prescribed dose in the past 2 months
- With contraindications to MRI examinations as per standard screening guidelines used in the Department of Radiology (i.e., ferromagnetic material or implants, pacemakers or defibrillators, stents, claustrophobia)
Other illness
- With signs and/or symptoms of central nervous system cancers (e.g., tumors, metastases, leptomeningial disease) as determined by their physician, medical records, or by a brain MRI, either at the time of enrollment or during the study period
- With current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report
- With history of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\>60 minutes), as per medical records or patient report
- With a history of another cancer, except for non-melanoma skin cancer, as per medical records or patient report
- With current substance abuse and/or history of substance abuse, as per medical records or patient report
- With evidence of visual or auditory impairment that would preclude completion of the assessments, as per medical records or patient report
Who the study is looking for
- Diagnosed with multiple myeloma and in complete, partial or very good partial remission at enrollment as per standard International Myeloma Working Group Criteria
- Scheduled to have high-dose chemotherapy and ASCT
- Age 60 - 75 years at study entry
- In the judgment of the consenting professional, fluent and able to communicate well enough in English to complete the study assessments and provide informed consent.
- Patients who report that English is not their primary language will be asked the US Census English proficiency question "How well do you speak English" and the answer "very well" will be required
Age in the registry: 60 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rutgers University - Data Analysis Coordinator of this site? Confirm its status | New Brunswick | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.